These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 22866924)

  • 21. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.
    Shimizu J; Horio Y; Osada H; Hida T; Hasegawa Y; Shimokata K; Takahashi T; Sekido Y; Yatabe Y
    Respirology; 2008 Jun; 13(4):510-7. PubMed ID: 18494946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer.
    Zheng Z; Li X; Schell MJ; Chen T; Boulware D; Robinson L; Sommers E; Bepler G
    Cancer; 2008 Jun; 112(12):2765-73. PubMed ID: 18442042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.
    Zhou H; Dai Y; Zhu L; Wang C; Fei X; Pan Q; Chen J; Shi X; Yang Y; Tao X; Shi P
    J Int Med Res; 2016 Feb; 44(1):89-98. PubMed ID: 26740498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.
    Nie X; Cheng G; Ai B; Zhang S
    Cancer Biomark; 2013 Jan; 13(6):433-40. PubMed ID: 24595080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA Repair Genes ERCC1 and BRCA1 Expression in Non-Small Cell Lung Cancer Chemotherapy Drug Resistance.
    Wang S; Liu F; Zhu J; Chen P; Liu H; Liu Q; Han J
    Med Sci Monit; 2016 Jun; 22():1999-2005. PubMed ID: 27289442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.
    Simon GR; Schell MJ; Begum M; Kim J; Chiappori A; Haura E; Antonia S; Bepler G
    Cancer; 2012 May; 118(9):2525-31. PubMed ID: 22028294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer.
    Liang JG; Jin ZY; Gao XD; Te MR; Ge LH; Wang CL
    Genet Mol Res; 2014 Jul; 13(3):5292-8. PubMed ID: 25078585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients.
    Li Y; Wang LR; Chen J; Lou Y; Zhang GB
    Dis Markers; 2014; 2014():960458. PubMed ID: 24591771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
    Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
    J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma.
    Ren S; Chen X; Kuang P; Zheng L; Su C; Li J; Li B; Wang Y; Liu L; Hu Q; Zhang J; Tang L; Li X; Zhou C; Schmid-Bindert G
    Cancer; 2012 Nov; 118(22):5588-94. PubMed ID: 22569898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy.
    Bonanno L; Costa C; Majem M; Sanchez JJ; Gimenez-Capitan A; Rodriguez I; Vergnenegre A; Massuti B; Favaretto A; Rugge M; Pallares C; Taron M; Rosell R
    Oncotarget; 2013 Oct; 4(10):1572-81. PubMed ID: 24197907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).
    Lee SM; Falzon M; Blackhall F; Spicer J; Nicolson M; Chaudhuri A; Middleton G; Ahmed S; Hicks J; Crosse B; Napier M; Singer JM; Ferry D; Lewanski C; Forster M; Rolls SA; Capitanio A; Rudd R; Iles N; Ngai Y; Gandy M; Lillywhite R; Hackshaw A
    J Clin Oncol; 2017 Feb; 35(4):402-411. PubMed ID: 27893326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.
    Tiseo M; Bordi P; Bortesi B; Boni L; Boni C; Baldini E; Grossi F; Recchia F; Zanelli F; Fontanini G; Naldi N; Campanini N; Azzoni C; Bordi C; Ardizzoni A;
    Br J Cancer; 2013 Apr; 108(8):1695-703. PubMed ID: 23549037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC.
    Vilmar A; Garcia-Foncillas J; Huarriz M; Santoni-Rugiu E; Sorensen JB
    Lung Cancer; 2012 Mar; 75(3):306-12. PubMed ID: 21996087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Rosell R; Danenberg KD; Alberola V; Bepler G; Sanchez JJ; Camps C; Provencio M; Isla D; Taron M; Diz P; Artal A;
    Clin Cancer Res; 2004 Feb; 10(4):1318-25. PubMed ID: 14977831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer.
    He YW; Zhao ML; Yang XY; Zeng J; Deng QH; He JX
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):861-7. PubMed ID: 25732635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.
    Mlak R; Krawczyk P; Ramlau R; Kalinka-Warzocha E; Wasylecka-Morawiec M; Wojas-Krawczyk K; Kucharczyk T; Homa I; Kozioł P; Ciesielka M; Chudziak D; Milanowski J
    Oncol Rep; 2013 Nov; 30(5):2385-98. PubMed ID: 23982437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applications of genomics in NSCLC.
    Rosell R; Cobo M; Isla D; Sanchez JM; Taron M; Altavilla G; Santarpia M; Moran T; Catot S; Etxaniz O
    Lung Cancer; 2005 Dec; 50 Suppl 2():S33-40. PubMed ID: 16557672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
    Shi Y; Chen L; Li J; Lü YL; Jiao SC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.